In lung cancer preclinical models, the administration of PAMPs or synthetic TLR2 ligands induced the differentiation of M1 macrophages that release nitric oxide, IFN-γ and pro-inflammatory cytokines, suggesting that TLR2 activation favors antitumor immune reactions [23]. This evidence concerns the gene TLR2 and lung cancer.